Literature DB >> 27339628

Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer.

Shinkyo Yoon1, Byung Woog Kang1, Su Yeon Park2, Hye Jin Kim2, Jun Seok Park2, Gyu Seog Choi2, Jong Gwang Kim3.   

Abstract

PURPOSE: Genetic polymorphisms in genes involved in the immune response are already known to affect the anti-tumor immune response. This study systematically investigated the association of 14 functional SNPs in a panel of 7 genes (CCL2, CCR2, NT5E, IDO1, LAG3, PDL1, and PDCD1) involved in immune response checkpoints with the survival outcomes of Korean patients with colorectal cancer (CRC).
METHODS: The genomic DNA from 668 patients with curatively resected CRC was analyzed using a Sequenom MassARRAY, along with the association with recurrence-free survival (RFS) and overall survival (OS).
RESULTS: Among the 14 SNPs, CCL2 rs4586 and PDCD1 rs10204525 were found to have an influence on the survival outcomes of the patients with resectable CRC. CCL2 rs4586 showed a significant correlation with OS in a recessive model in a univariate analysis, as well as a multivariate analysis. In addition, PDCD1 rs10204525 revealed a significant association with RFS and OS in a recessive model in a univariate analysis and exhibited a significant impact in a multivariate analysis.
CONCLUSION: In conclusion, this results suggest that the genetic predisposition of the host may affect the anti-tumor immune reaction in CRC. The results of this study may also be helpful when selecting targets for novel drug development to promote the anti-tumor immune response.

Entities:  

Keywords:  Colorectal cancer; Genetic polymorphism; Immune checkpoint; Prognostic marker

Mesh:

Year:  2016        PMID: 27339628     DOI: 10.1007/s00432-016-2196-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Duk Hyoung Lee; Jin Soo Lee
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 3.  Chemokines in the pathogenesis of vascular disease.

Authors:  Israel F Charo; Mark B Taubman
Journal:  Circ Res       Date:  2004-10-29       Impact factor: 17.367

4.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

5.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.

Authors:  Bin-Zhi Qian; Jiufeng Li; Hui Zhang; Takanori Kitamura; Jinghang Zhang; Liam R Campion; Elizabeth A Kaiser; Linda A Snyder; Jeffrey W Pollard
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

6.  Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Authors:  Hiroyuki Suzuki; Nobuhito Chikazawa; Takehiko Tasaka; Junji Wada; Akio Yamasaki; Yoshiki Kitaura; Masae Sozaki; Masao Tanaka; Hideya Onishi; Takashi Morisaki; Mitsuo Katano
Journal:  Cancer Immunol Immunother       Date:  2009-11-12       Impact factor: 6.968

7.  Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Authors:  Stephen Mok; Richard C Koya; Christopher Tsui; Jingying Xu; Lídia Robert; Lily Wu; Thomas Graeber; Brian L West; Gideon Bollag; Antoni Ribas
Journal:  Cancer Res       Date:  2013-11-18       Impact factor: 12.701

8.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression.

Authors:  Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce
Journal:  Nat Med       Date:  2013-09-22       Impact factor: 53.440

9.  Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

Authors:  Stephen Mok; Jennifer Tsoi; Richard C Koya; Siwen Hu-Lieskovan; Brian L West; Gideon Bollag; Thomas G Graeber; Antoni Ribas
Journal:  BMC Cancer       Date:  2015-05-05       Impact factor: 4.430

10.  Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer.

Authors:  H E Lee; S W Chae; Y J Lee; M A Kim; H S Lee; B L Lee; W H Kim
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more
  4 in total

1.  Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes.

Authors:  Brittany N Chao; Danielle M Carrick; Kelly K Filipski; Stefanie A Nelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

Review 2.  Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.

Authors:  Marilina García-Aranda; Maximino Redondo
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

3.  Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis.

Authors:  Ramy R Saleh; Paloma Peinado; Jesús Fuentes-Antrás; Pedro Pérez-Segura; Atanasio Pandiella; Eitan Amir; Alberto Ocaña
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

Review 4.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.